Rhythm Pharmaceuticals Announces Update to September Conference Participation
September 08, 2023 07:59 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
September 06, 2023 07:59 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals to Present at Investor Conferences in September
August 28, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
August 07, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access designation for hypothalamic obesity comes in addition...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
August 04, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
August 01, 2023 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE® (setmelanotide) -- -- Strong U.S. commercial progress continues with more than 125 new prescriptions for...
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
July 19, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
July 17, 2023 06:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 17, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
July 13, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
June 17, 2023 14:01 ET
|
Rhythm Pharmaceuticals, Inc.
-- Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean BMI reduction at 16 weeks -- -- Phase 3 trial evaluating setmelanotide in...